Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $90.50.

Several research firms recently weighed in on TARS. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Guggenheim reduced their target price on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a report on Friday, April 24th. They issued an “outperform” rating and a $98.00 target price for the company.

Insider Activity

In other Tarsus Pharmaceuticals news, insider Jeffrey S. Farrow sold 14,396 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $60.95, for a total value of $877,436.20. Following the completion of the sale, the insider owned 56,801 shares of the company’s stock, valued at $3,462,020.95. This trade represents a 20.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Bobak R. Azamian sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total value of $615,500.00. Following the transaction, the chief executive officer directly owned 847,991 shares in the company, valued at approximately $52,193,846.05. This represents a 1.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 39,850 shares of company stock valued at $2,452,821. Company insiders own 9.64% of the company’s stock.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Rockefeller Capital Management L.P. lifted its stake in Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after acquiring an additional 172 shares during the period. Parallel Advisors LLC increased its position in Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after purchasing an additional 291 shares during the period. State of Wisconsin Investment Board raised its holdings in shares of Tarsus Pharmaceuticals by 1.1% in the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock valued at $2,613,000 after purchasing an additional 332 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 0.6% in the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after purchasing an additional 339 shares in the last quarter. Finally, Valeo Financial Advisors LLC lifted its position in shares of Tarsus Pharmaceuticals by 11.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after purchasing an additional 392 shares during the period. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Up 1.8%

Shares of TARS stock opened at $57.26 on Wednesday. Tarsus Pharmaceuticals has a 1 year low of $38.51 and a 1 year high of $85.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. The stock’s 50 day simple moving average is $61.89 and its two-hundred day simple moving average is $66.39. The company has a market cap of $2.46 billion, a PE ratio of -50.23 and a beta of 0.50.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.24. The business had revenue of $162.05 million during the quarter, compared to analyst estimates of $149.60 million. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%. Research analysts predict that Tarsus Pharmaceuticals will post -0.86 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.